
Currently out of the existing stock ratings of Difei Yang, 245 are a BUY (92.11%), 20 are a HOLD (7.52%), 1 are a SELL (0.38%).
Analyst Difei Yang, has had 51.19% of price targets met with an average potential upside of 45.37%, reached in 454 days on average. Previously, Difei Yang worked at MIZUHO, AEGIS, BREAN.
Difei Yang has documented 539 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on MGTA, Magenta Therapeutics at 18-Apr-2022.
Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) on 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%), with a performance score of 94.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Dec-2019
$15.25
$13
4 years 2 months 22 days ago
(29-Aug-2022)
2/7 (28.57%)
$0.18 (1.19%)
109
Buy Since 07-May-2020
$15.25
$29
4 years 2 months 27 days ago
(24-Aug-2022)
1/2 (50%)
$0.07 (0.46%)
47
Buy Since 16-Feb-2018
$20
4 years 2 months 27 days ago
(24-Aug-2022)
0/6 (0%)
$14.21 (245.42%)
Buy Since 19-Nov-2013
$15.25
$27
4 years 2 months 28 days ago
(23-Aug-2022)
10/14 (71.43%)
$0.09 (0.59%)
161
Buy Since 22-Oct-2019
$15.25
$30
4 years 2 months 28 days ago
(23-Aug-2022)
1/3 (33.33%)
$0.09 (0.59%)
48